Literature DB >> 578267

Withdrawal of antihypertensive therapy. Hypertensive crisis in renovascular hypertension.

F G Strauss, S S Franklin, A J Lewin, M H Maxwell.   

Abstract

Hypertensive crises were reported in three patients with hypertension associated with underlying renovascular occlusive disease during reduction of antihypertensive therapy. In each case, rebound hypertension was observed during clonidine hydrochloride withdrawal. Therapy with propranolol hydrochloride and diuretics had also been discontinued in two of the three patients. This and other reports of rebound hypertension during clonidine withdrawal are contrasted with the absence of reports of this syndrome in the setting of cessation of beta-adrenergic blockade therapy. This suggests that the discontinuation of clonidine therapy was primarily responsible for the hypertensive crises herein described. It is further concluded that rebound hypertension may follow gradual as well as abrupt reduction of clonidine dosage, and that patients with renovascular hypertension may be at greatest risk.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 578267

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  5 in total

1.  New aspects of the pharmacokinetics and pharmacodynamics of clonidine in man.

Authors:  D Arndts; J Doevendans; R Kirsten; B Heintz
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 2.  Adverse effects of antihypertensive drugs.

Authors:  F E Husserl; F H Messerli
Journal:  Drugs       Date:  1981-09       Impact factor: 9.546

3.  Clonidine hydrochloride withdrawal complicating bilateral nephrectomy.

Authors:  T P Mate; A H Swerdlin; R A Stone; S M Steinberg
Journal:  West J Med       Date:  1979-07

Review 4.  Clinical consequences of abrupt drug withdrawal.

Authors:  C F George; D Robertson
Journal:  Med Toxicol Adverse Drug Exp       Date:  1987 Sep-Oct

Review 5.  Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder.

Authors:  J S Markowitz; K S Patrick
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.